• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

加拿大斑块型银屑病管理指南:概述。

Canadian guidelines for the management of plaque psoriasis: overview.

机构信息

K.Papp Clinical Research, Waterloo, ON, Canada.

出版信息

J Cutan Med Surg. 2011 Jul-Aug;15(4):210-9. doi: 10.2310/7750.2011.10066.

DOI:10.2310/7750.2011.10066
PMID:21781627
Abstract

New clinical treatment guidelines for plaque psoriasis, written by a panel of 16 Canadian dermatologists, were recently published online. These Canadian Guidelines for the Management of Plaque Psoriasis are evidence based and free of any influence from corporate sponsors and have been endorsed by the Canadian Dermatology Association (CDA). The Guidelines offer treatment recommendations for mild and moderate to severe body psoriasis, as well as for psoriasis affecting specific areas of the skin, such as the facial, flexural, and genital areas; nails; scalp; and palms and soles. The present overview describes the genesis and contents of the Guidelines, which are available in full through the CDA at http://www.dermatology.ca/guidelines/cdnpsoriasisguidelines.pdf (English) or http://www.dermatology.ca/french/psoriasisguidelines.html (French).

摘要

最近,由 16 位加拿大皮肤科医生组成的专家组发布了新版斑块状银屑病临床治疗指南。这些加拿大斑块状银屑病管理指南是基于证据的,不受任何企业赞助商的影响,并得到了加拿大皮肤科医师协会(CDA)的认可。该指南为轻度和中度至重度体部银屑病,以及影响皮肤特定区域(如面部、屈肌和生殖器区域;指甲;头皮;手掌和足底)的银屑病提供了治疗建议。本概述描述了指南的起源和内容,可在 CDA 上全文查阅,网址为http://www.dermatology.ca/guidelines/cdnpsoriasisguidelines.pdf(英文)或http://www.dermatology.ca/french/psoriasisguidelines.html(法文)。

相似文献

1
Canadian guidelines for the management of plaque psoriasis: overview.加拿大斑块型银屑病管理指南:概述。
J Cutan Med Surg. 2011 Jul-Aug;15(4):210-9. doi: 10.2310/7750.2011.10066.
2
A patient decision aid for psoriasis based on current clinical practice guidelines.基于当前临床实践指南的银屑病患者决策辅助工具。
Arch Dermatol. 2012 Jun;148(6):718-23. doi: 10.1001/archdermatol.2012.36.
3
German S3-guidelines on the treatment of psoriasis vulgaris (short version).德国 S3 指南:寻常型银屑病治疗(简版)。
Arch Dermatol Res. 2012 Mar;304(2):87-113. doi: 10.1007/s00403-012-1214-8. Epub 2012 Feb 17.
4
Dermatologists' Perspectives on Defining Moderate Psoriasis: The Canadian Moderate Psoriasis Survey.皮肤科医生对中度银屑病定义的看法:加拿大中度银屑病调查。
J Drugs Dermatol. 2021 Feb 1;20(2):126-132. doi: 10.36849/JDD.5531.
5
Comparison of Guidelines for the Use of Cyclosporine for Psoriasis: A Critical Appraisal and Comprehensive Review.银屑病环孢素使用指南的比较:批判性评估与全面综述
J Drugs Dermatol. 2016 Mar;15(3):293-301.
6
S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update.S3 - 寻常型银屑病治疗指南(英文版)。更新版。
J Dtsch Dermatol Ges. 2012 Mar;10 Suppl 2:S1-95. doi: 10.1111/j.1610-0387.2012.07919.x.
7
Knowledge, attitudes and use of the guidelines for the treatment of moderate to severe plaque psoriasis among Dutch dermatologists.荷兰皮肤科医生对中度至重度斑块状银屑病治疗指南的知晓情况、态度及应用情况
Br J Dermatol. 2008 Aug;159(2):426-32. doi: 10.1111/j.1365-2133.2008.08692.x. Epub 2008 Jul 4.
8
Evidence-based recommendations to assess psoriasis severity: systematic literature review and expert opinion of a panel of dermatologists.基于证据的银屑病严重程度评估建议:系统文献回顾和一组皮肤科医生专家意见。
J Eur Acad Dermatol Venereol. 2010 Apr;24 Suppl 2:2-9. doi: 10.1111/j.1468-3083.2009.03561.x.
9
Evidence-based guidelines of the spanish psoriasis group on the use of biologic therapy in patients with psoriasis in difficult-to-treat sites (nails, scalp, palms, and soles).西班牙银屑病小组关于在治疗困难部位(指甲、头皮、手掌和脚底)的银屑病患者中使用生物疗法的循证指南。
Actas Dermosifiliogr. 2014 Dec;105(10):923-34. doi: 10.1016/j.ad.2014.02.015. Epub 2014 May 19.
10
Epidemiology of moderate-to-severe plaque psoriasis in a Canadian surveyed population.加拿大调查人群中中重度斑块状银屑病的流行病学。
J Cutan Med Surg. 2010 Jul-Aug;14(4):167-74. doi: 10.2310/7750.2010.09066.

引用本文的文献

1
Comorbid psoriasis in systemic lupus erythematosus: a cohort study from a tertiary referral centre and the National Patient Register in Sweden.系统性红斑狼疮合并银屑病:一项来自瑞典三级转诊中心和国家患者登记处的队列研究。
Lupus Sci Med. 2025 Jun 4;12(1):e001504. doi: 10.1136/lupus-2025-001504.
2
Drug Insurance and Psoriasis Severity: A Retrospective Cohort Study.药物保险与银屑病严重程度:一项回顾性队列研究
J Health Econ Outcomes Res. 2025 Feb 7;12(1):51-57. doi: 10.36469/001c.127820. eCollection 2025.
3
Canadian Expert Consensus on the Use of Halobetasol Propionate/Tazarotene Lotion for Plaque Psoriasis.
加拿大关于使用丙酸氯倍他索/他扎罗汀洗剂治疗斑块状银屑病的专家共识。
Dermatol Ther (Heidelb). 2024 Jul;14(7):1917-1928. doi: 10.1007/s13555-024-01204-1. Epub 2024 Jun 25.
4
A partitioned 88-loci psoriasis genetic risk score reveals HLA and non-HLA contributions to clinical phenotypes in a Newfoundland psoriasis cohort.一个包含88个位点的银屑病遗传风险评分分区揭示了在纽芬兰银屑病队列中HLA和非HLA对临床表型的影响。
Front Genet. 2023 May 31;14:1141010. doi: 10.3389/fgene.2023.1141010. eCollection 2023.
5
Psoriasis: A Primer for General Physicians.银屑病:全科医生入门指南。
Cureus. 2023 Apr 24;15(4):e38037. doi: 10.7759/cureus.38037. eCollection 2023 Apr.
6
Challenges in Psoriatic Disease Addressed by Fixed-Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion.0.01%丙酸氯倍他索与0.045%他扎罗汀固定复方洗剂应对银屑病的挑战。
J Clin Aesthet Dermatol. 2023 Mar;16(3):21-26.
7
Trajectories of systemic agent use and associated depression- and anxiety-related health care costs among patients with psoriasis.银屑病患者全身用药轨迹及相关的抑郁和焦虑相关医疗保健费用
JAAD Int. 2022 Jun 25;9:11-22. doi: 10.1016/j.jdin.2022.06.018. eCollection 2022 Dec.
8
Reactivation rates of hepatitis B or C or HIV in patients with psoriasis using biological therapies: a systematic review and meta-analysis.生物治疗银屑病患者乙型肝炎或丙型肝炎或 HIV 的再激活率:系统评价和荟萃分析。
Clin Exp Med. 2023 Jul;23(3):701-715. doi: 10.1007/s10238-022-00827-y. Epub 2022 Apr 30.
9
Certolizumab Pegol Use in the Treatment of Moderate-to-Severe Psoriasis: Real-World Data From Two Canadian Centers.培戈利珠单抗治疗中重度银屑病的疗效:来自加拿大两个中心的真实世界数据。
J Cutan Med Surg. 2022 May-Jun;26(3):267-273. doi: 10.1177/12034754221078203. Epub 2022 Feb 8.
10
Treatment satisfaction, safety and effectiveness of adding methotrexate to adalimumab in patients with psoriasis responding suboptimally to adalimumab in a real-world setting.在现实环境中,对于对阿达木单抗反应欠佳的银屑病患者,在阿达木单抗基础上加用甲氨蝶呤的治疗满意度、安全性及有效性。
Br J Dermatol. 2022 Apr;186(4):726-728. doi: 10.1111/bjd.20885. Epub 2022 Jan 20.